Entera Bio Announces $275M Private Placement; BVF Board Seats

What Happened

• Entera Bio Ltd. announced a private placement under a Securities Purchase Agreement signed July 26, 2026 and closed July 28, 2026, raising approximately $275.0 million through the sale of 134,803,910 securities at $2.04 per ordinary share (122,961,215 Ordinary Shares issued and 11,842,695 Pre‑Funded Warrants issued).
• Proceeds are intended to support initiation of the Company’s Phase 3 registrational study of EB613 in postmenopausal women with osteoporosis and for general working capital and corporate purposes. Leerink Partners acted as lead placement agent; several firms served as co-placement agents.

Key Details

• Amount raised: ~ $275.0 million; price: $2.04 per Ordinary Share; total securities sold: 134,803,910 (split into 122,961,215 Ordinary Shares and 11,842,695 Pre‑Funded Warrants).
• Pre‑Funded Warrants: exercise price NIS 0.0000769 per share, immediately exercisable, no expiration, customary adjustments; exercise limited to avoid exceeding holder ownership caps (4.99% or 9.99% opt-in, with possible increase up to 19.99%).
• Board designation rights: BVF Partners received the right to designate two directors initially (subject to legal/Nasdaq qualifications). The designation right reduces to one if BVF’s ownership of the purchased securities falls below 75%, and terminates if below 50% of those securities or below 10% of issued and outstanding Ordinary Shares.
• Corporate governance / shareholder votes: Purchasers agreed to vote in favor of proposals to (1) increase shares available under the 2018 Equity Incentive Plan and (2) grant equity to certain executives to restore their pre‑deal ownership percentages; the Company expects a special shareholder meeting in Q4 2026 (no later than 12 months post‑closing).
• Registration rights: Company to file a registration statement for resale of the Ordinary Shares and shares issuable upon exercise of the Pre‑Funded Warrants within 30 days of closing and use reasonable best efforts to get it declared effective; warrants may be exercised cashless if resale registration is not effective.

Why It Matters

• Capital and clinical progress: The financing provides a material cash infusion (~$275M) to fund Entera’s planned Phase 3 study of EB613 and general operations, which can materially affect the company’s development timeline and cash runway.
• Dilution and governance impact: The issuance of shares and warrants dilutes existing shareholders; BVF’s ability to designate board members gives it direct influence over board composition and potentially strategy while its designation rights remain in effect.
• Future shareholder approvals and potential additional dilution: The company will seek shareholder approval for incentive-plan increases and executive equity grants, which, if approved, would further increase outstanding shares. Registration rights also affect when investors can resell their shares and whether cashless warrant exercise will be used.

Exhibits to the 8‑K include the Purchase Agreement, form of Pre‑Funded Warrant, and Registration Rights Agreement (filed as exhibits).